Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomised, placebo-controlled study
- 31 January 1992
- journal article
- Published by Elsevier in Fibrinolysis
- Vol. 6 (1), 45-50
- https://doi.org/10.1016/0268-9499(92)90047-l
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation productsBlood, 1990
- Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humansBlood, 1989
- Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cellsBlood, 1989
- Promotion and Subsequent Inhibition of Plasminogen Activation after Administration of Intravenous Endotoxin to Normal SubjectsNew England Journal of Medicine, 1989
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- On the Usefulness of Fibrinolysis Variables in the Characterization of a Risk Group for Myocardial ReinfarctionActa Medica Scandinavica, 1987
- Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1.Journal of Clinical Investigation, 1986
- Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor.The Journal of Experimental Medicine, 1986
- Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells.Journal of Clinical Investigation, 1986
- Plasminogen activator inhibitor in the blood of patients with coronary artery disease.BMJ, 1985